Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE | Q9Y2I7 | 6/20 | 0.68 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | CSF1R | P07333 | 4/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | TEK | Q02763 | 3/20 | 0.55 |
| ▸ | BRAF | P15056 | 4/20 | 0.54 |
| ▸ | ABL1 | P00519 | 3/20 | 0.54 |
| ▸ | YES1 | P07947 | 3/20 | 0.54 |
| ▸ | BCR | P11274 | 3/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.54 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.54 |
| ▸ | ESYT2 | A0FGR8 | 2/20 | 0.54 |
| ▸ | NBAS | A2RRP1 | 2/20 | 0.54 |
| ▸ | CNOT1 | A5YKK6 | 2/20 | 0.54 |
| ▸ | TBKBP1 | A7MCY6 | 2/20 | 0.54 |
| ▸ | AGPS | O00116 | 2/20 | 0.54 |
| ▸ | MYO1F | O00160 | 2/20 | 0.54 |
| ▸ | SNAP23 | O00161 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943516 | 0.94 | PIKFYVE (0.75) | PIKFYVEKDRCSF1RMAPK14KIT | |
| SCHEMBL21943533 | 0.92 | KDR (0.58) | PIKFYVEKDRCSF1RMAPK14KIT | |
| SCHEMBL21943014 | 0.88 | PIKFYVE (0.65) | PIKFYVEKDRCSF1RMAPK14KIT | |
| SCHEMBL21943007 | 0.87 | PIKFYVE (0.61) | PIKFYVEKDRCSF1RMAPK14KIT | |
| SCHEMBL21944047 | 0.87 | PIKFYVE (0.67) | PIKFYVEKDRCSF1RMAPK14TEK | |
| SCHEMBL21943518 | 0.86 | PIKFYVE (0.64) | PIKFYVEKDRCSF1RMAPK14KIT | |
| SCHEMBL22024551 | 0.86 | PIKFYVE (0.88) | PIKFYVEKDRCSF1RMAPK14KIT | |
| SCHEMBL21943534 | 0.85 | KDR (0.58) | PIKFYVEKDRCSF1RMAPK14KIT | |
| SCHEMBL30692257 | 0.84 | MAP3K7 (0.70) | PIKFYVEKDRCSF1RMAPK14KIT | |
| SCHEMBL12518525 | 0.84 | MAP3K7 (0.70) | PIKFYVEKDRCSF1RMAPK14KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | XIAMEN UNIVERSITY (CN) | 2022-05-03 | — | — | US | disclosed |
| EP-3647313-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Xiamen University (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP4A11, CYP2D6, CYP3A43 | PIKFYVE 2706/4885KDR 2067/4885CSF1R 3749/4885 |
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | CYP4A11, CYP2D6, CYP3A43 | PIKFYVE 2706/4885KDR 2067/4885CSF1R 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.